Although most studies focus on the clinical efficacy, Omalizumab therapy has been shown to reduce peripheral blood eosinophilia and restore numbers of CD4+Foxp3+CD25+CD127lo Treg, correlating with the level of asthma control (Amat et al., 2016). This evidence concerns the gene CD4 and Increased total eosinophil count.